Nucs AI is off to Madrid for ESMO'26!
‍
Our CEO Nijat Ahmadov, CTO Farid Yagubbayli and COO Will Plogger will be attending this year's congress.

Following EANM in Vienna, we're excited to engage in discussions about the latest advances in oncology research and cancer treatment. As radioligand therapies move further into oncology practice, molecular imaging is becoming increasingly important for patient selection and treatment response assessment.

Reach out to us at nucs.ai/contact